{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:12:13Z","timestamp":1747267933725,"version":"3.28.0"},"reference-count":47,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hemophilia A\/B are caused by deficiency or lack of coagulation factors VIII (FVIII) or factor IX (FIX), respectively, in plasma. A person with hemophilia develops bleeding in the joints and muscles at an early age, which, if left untreated, leads to early arthropathy. Preventive treatment can be achieved by regular (prophylactic) administration of FVIII\/FIX. In 1958, this was implemented on a small scale in Sweden with FVIII in patients with severe hemophilia A, and in those with hemophilia B in 1972 when FIX became available. However, there were problems with human immunodeficiency virus and hepatitis infection from contaminated blood products. In the 1990s, recombinant FVIII and FIX concentrates were introduced. The major remaining problems then were the development of inhibitors, and the need for a venous route for the injections in very young children. High-titer inhibitors were treated by immune tolerance induction according to a modified model of the original Bonn high-dose protocol. A central venous line, i.e., Port-A-Cath, has enabled early prophylaxis in many children with poor venous access and has enabled the early start of home treatment with adequate injection frequency. Scoring systems for X-rays, magnetic resonance imaging, and function of joints were developed early in Sweden and have been widely disseminated worldwide, partly with modifications. Extended half-life products with half-life increased three to five times have been developed, which can provide superior bleed protection when dosed once-weekly and can maintain therapeutic trough levels when administered less frequently. The ultimate prophylaxis therapy in the future may be gene therapy.<\/jats:p>","DOI":"10.1055\/s-0044-1782518","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:12:47Z","timestamp":1710807167000},"page":"714-719","source":"Crossref","is-referenced-by-count":5,"title":["Prophylactic Treatment of Children with Hemophilia in Sweden"],"prefix":"10.1055","volume":"50","author":[{"given":"Rolf","family":"Ljung","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund \u2013 Pediatrics, Lund University, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"issue":"S 77","key":"ref1","first-page":"77","article-title":"Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B","author":"A Ahlberg","year":"1965","journal-title":"Acta Orthop Scand Suppl"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.0954-6820.1958.tb15547.x","article-title":"Treatment of hemophilia A with human antihemophilic globulin","volume":"161","author":"M Blomback","year":"1958","journal-title":"Acta Med Scand"},{"key":"ref3","first-page":"111","article-title":"Our experience in Sweden with prophylaxis on haemophilia","volume":"34","author":"I M Nilsson","year":"1970","journal-title":"Bibl Haematol"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1651-2227.1976.tb16525.x","article-title":"Haemophilia prophylaxis in Sweden","volume":"65","author":"I M Nilsson","year":"1976","journal-title":"Acta Paediatr Scand"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.2196\/resprot.6558","article-title":"Development of a web-accessible population pharmacokinetic service-hemophilia (WAPPS-Hemo): study protocol","volume":"5","author":"A Iorio","year":"2016","journal-title":"JMIR Res Protoc"},{"issue":"S 04","key":"ref6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2516.2012.02838.x","article-title":"Personalized prophylaxis","volume":"18","author":"P W Collins","year":"2012","journal-title":"Haemophilia"},{"issue":"07","key":"ref7","first-page":"233","article-title":"A controlled study of long-term treatment of haemophilia B on an out-patient basis (author's transl) [in German]","volume":"101","author":"K Schimpf","year":"1976","journal-title":"Dtsch Med Wochenschr"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.1976.tb00973.x","article-title":"Prophylaxis in haemophilia: a double-blind controlled trial","volume":"33","author":"A Aronstam","year":"1976","journal-title":"Br J Haematol"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/hae.12838","article-title":"A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia - A success story from a resource limited country","volume":"22","author":"S P Verma","year":"2016","journal-title":"Haemophilia"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2516.2010.02348.x","article-title":"Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China","volume":"17","author":"R Wu","year":"2011","journal-title":"Haemophilia"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B","volume":"232","author":"I M Nilsson","year":"1992","journal-title":"J Intern Med"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1600-0609.1987.tb01173.x","article-title":"HIV seroconversion in Swedish haemophiliacs: relation to type and dosage of factor concentrate","volume":"38","author":"E Berntorp","year":"1987","journal-title":"Eur J Haematol"},{"issue":"08","key":"ref13","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1651-2227.2002.tb02854.x","article-title":"Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey","volume":"91","author":"K E Knobe","year":"2002","journal-title":"Acta Paediatr"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"S C Gouw","year":"2013","journal-title":"N Engl J Med"},{"issue":"21","key":"ref15","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"F Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/hae.12854","article-title":"Mutation analysis of Swedish haemophilia B families - high frequency of unique mutations","volume":"22","author":"A M\u00e5rtensson","year":"2016","journal-title":"Haemophilia"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2019.239160","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study","volume":"106","author":"C Male","year":"2021","journal-title":"Haematologica"},{"issue":"20","key":"ref18","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"S C Gouw","year":"2013","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(77)90871-6","article-title":"Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder","volume":"2","author":"H H Brackmann","year":"1977","journal-title":"Lancet"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.15053","article-title":"How I manage patients with inherited haemophilia A and B and factor inhibitors","volume":"180","author":"R CR Ljung","year":"2018","journal-title":"Br J Haematol"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2516.1999.00195.x","article-title":"Tolerance induction using the Malm\u00f6 treatment model 1982-1995","volume":"5","author":"C Freiburghaus","year":"1999","journal-title":"Haemophilia"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/pbc.24856","article-title":"Increased burden on caregivers of having a child with haemophilia complicated by inhibitors","volume":"61","author":"K Lindvall","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"S 01","key":"ref23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-2516.9.s1.16.x","article-title":"How to start prophylaxis","volume":"9","author":"P Petrini","year":"2003","journal-title":"Haemophilia"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1538-7836.2006.01953.x","article-title":"Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study","volume":"4","author":"B M Feldman","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1651-2227.1992.tb12135.x","article-title":"Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia","volume":"81","author":"R Ljung","year":"1992","journal-title":"Acta Paediatr"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0268-960X(03)00043-2","article-title":"Central venous catheters in children with haemophilia","volume":"18","author":"R Ljung","year":"2004","journal-title":"Blood Rev"},{"issue":"149","key":"ref27","first-page":"153","article-title":"A radiologic classification of hemophilic arthropathy","author":"H Pettersson","year":"1980","journal-title":"Clin Orthop Relat Res"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1651-2227.1981.tb05741.x","article-title":"Radiologic evaluation of prophylaxis in severe haemophilia","volume":"70","author":"H Pettersson","year":"1981","journal-title":"Acta Paediatr Scand"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1651-2227.1980.tb07341.x","article-title":"Arthropathy in children with severe hemophilia A","volume":"69","author":"J Soreff","year":"1980","journal-title":"Acta Paediatr Scand"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2516.2004.00902.x","article-title":"A new magnetic resonance imaging scoring method for assessment of haemophilic arthropathy","volume":"10","author":"B Lundin","year":"2004","journal-title":"Haemophilia"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2516.2005.01061.x","article-title":"MRI scores of ankle joints in children with haemophilia\u2013comparison with clinical data","volume":"11","author":"B Lundin","year":"2005","journal-title":"Haemophilia"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/hae.14693","article-title":"Haemophilia A and B - evaluation of the Swedish prophylactic regimen by magnetic resonance imaging","volume":"29","author":"B Lundin","year":"2023","journal-title":"Haemophilia"},{"issue":"02","key":"ref33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1046\/j.1365-2516.2003.00746.x","article-title":"Third and fourth Workshops of the European Paediatric Network for Haemophilia Management","volume":"9","author":"F G Hill","year":"2003","journal-title":"Haemophilia"},{"issue":"02","key":"ref34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/acr.20353","article-title":"Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score","volume":"63","author":"B M Feldman","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"02","key":"ref35","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/bjh.14844","article-title":"Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment","volume":"179","author":"N G Andersson","year":"2017","journal-title":"Br J Haematol"},{"issue":"S 01","key":"ref36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2516.2008.01948.x","article-title":"Haemophilia care in adolescents\u2013compliance and lifestyle issues","volume":"15","author":"P Petrini","year":"2009","journal-title":"Haemophilia"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1365-2516.2012.02879.x","article-title":"Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy","volume":"18","author":"K Lindvall","year":"2012","journal-title":"Haemophilia"},{"key":"ref38","first-page":"20","article-title":"International consensus recommendations on the management of people with haemophilia B","volume":"13","author":"D P Hart","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"22","key":"ref39","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1182\/blood.2018884015","article-title":"Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B model","volume":"133","author":"B Cooley","year":"2019","journal-title":"Blood"},{"issue":"07","key":"ref40","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1111\/jth.15741","article-title":"Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII","volume":"20","author":"M Demers","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref41","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"A von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"issue":"09","key":"ref42","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"J Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"09","key":"ref43","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"K J Pasi","year":"2017","journal-title":"N Engl J Med"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/hae.13260","article-title":"Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay","volume":"23","author":"E K Waters","year":"2017","journal-title":"Haemophilia"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood-2016-05-718635","article-title":"Design and characterization of an APC-specific serpin for the treatment of hemophilia","volume":"129","author":"S G Polderdijk","year":"2017","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14936","article-title":"Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment","author":"E Symington","year":"2024","journal-title":"Haemophilia"},{"issue":"01","key":"ref47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/hae.14882","article-title":"Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B","volume":"30","author":"R Klamroth","year":"2024","journal-title":"Haemophilia"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1782518.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:18:31Z","timestamp":1730805511000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1782518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":47,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2024,6,11]]},"published-print":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1782518","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"type":"print","value":"0094-6176"},{"type":"electronic","value":"1098-9064"}],"subject":[],"published":{"date-parts":[[2024,3,18]]}}}